Drug Trial Radar · NCT07297914
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Jan 7, 2026
Primary completion
Nov 30, 2032
Study completion Dec 1, 2032
Sponsor
- Lead sponsor
- Bambino Gesù Hospital and Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 months, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Current therapeutic strategies for high-risk or relapsed ALL patients often involve intensive treatments, including allogeneic hematopoietic stem cell transplantation (HSCT). HSCT remains a cornerstone of therapy, offering curative potential; however, it is associated with considerable risks, including non-relapse mortality (NRM), significant morbidity, and long-term complications that continue to be major concerns. In response to these challenges, the FORUM consortium has made substantial progress in improving outcomes for children with ALL undergoing HSCT. The consortium focuses on reducing life-threatening and lifelong complications, ultimately aiming to enhance quality of life for these high-risk patients. Building on the robust evidence generated by FORUM1, the FORUM2 study has been designed to further optimize the role of HSCT in ALL across all age groups and donor settings within a harmonized and internationally coordinated framework. The FORUM2 study introduces a master protocol structure that encompasses multiple hypothesis-driven substudies, each addressing a specific determinant of HSCT outcomes. This design enables simultaneous or sequential evaluation of novel strategies while ensuring uniform governance, endpoint definitions, and data-quality standards. The overarching objective is to refine the role of HSCT in ALL by reducing treatment-related toxicity while preserving the essential graft-versus-leukemia effect.
Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Stem Cell Transplant
- Graft -Versus-host-disease
Interventions
Total Body Irradiation 8 GyRadiation
Total Body Irradiation 8 Gy administered in combination with VP16 as part of the conditioning regimen
RuxolitinibCombination product
Ruxolitinib plus corticosteroids in treatment-naïve acute graft-versus-host disease
BlinatumomabDrug
Up to four cycles of blinatumomab as post-HSCT maintenance therapy
CyclophosphamideDrug
In vivo T-cells depletion/modulation with post-transplant cyclophosphamide
Total Body Irradiation 12 GyRadiation
Total Body Irradiation 12 Gy administered in combination with VP16 as part of the conditioning regimen
CorticosteroidsDrug
Corticosteroids alone in treatment-naïve acute graft-versus-host disease
αβ T-cells depletionOther
Ex vivo graft manipulation based on selective depletion of T-cell receptor αβ (TCR αβ+)/CD19+ lymphocytes from the graft (αβ T-cells depletion)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event Free Survival (EFS)Time frame: at year 4
- Overall response rate (ORR) at day 28Time frame: day 28
- Event Free Survival (EFS)Time frame: at year 4
- Cumulative incidence of relapse (CIR) at 2 years after HSCTTime frame: 2 years after HSCT
Locations
9 sites in 9 countries. Site status is shown where the registry gives one.
St'Anna Children Hospital
Vienna, Austria · Not yet recruiting
University Hospital Motol
Prague, Czechia · Recruiting
Rigshopsitalet, University Hospital
Copenhagen, Denmark · Not yet recruiting
HUS-Yhtymae (HUS Helsinki University Hospital)
Helsinki, Finland · Not yet recruiting
Robert- Debré Academic Hospital
Paris, France · Not yet recruiting
Goethe-Universität
Frankfurt, Germany · Recruiting
IRCCS Ospedale Pediatrico Bambino Gesù
Roma, RM, Italy · Not yet recruiting
University Hospital
Oslo, Norway · Active not recruiting
University of Medical Sciences
Poznan, Poland · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.